©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2024; 16(5): 678-683
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.678
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.678
Fecal microbiota transplantation in the treatment of hepatic encephalopathy: A perspective
Arghya Samanta, Moinak Sen Sarma, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
Author contributions: Samanta A did the literature review and wrote the original manuscript; Sen Sarma M did critical analysis, reviewed and revised the manuscript; All authors approved the final version of the manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest.
Corresponding author: Moinak Sen Sarma, MBBS, MD, Adjunct Associate Professor, Doctor, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, India. moinaksen@yahoo.com
Received: January 23, 2024
Revised: March 6, 2024
Accepted: April 16, 2024
Published online: May 27, 2024
Processing time: 119 Days and 23.8 Hours
Revised: March 6, 2024
Accepted: April 16, 2024
Published online: May 27, 2024
Processing time: 119 Days and 23.8 Hours
Core Tip
Core Tip: Hepatic encephalopathy (HE) remains one of the most dreaded and difficult-to-treat complications in patients with cirrhosis. Alteration in the number and diversity of microorganisms in the human intestinal tract appears to have profound effect in the pathophysiology of HE in cirrhotic patients. Targeting gut dysbiosis by fecal microbiota transplantation is a promising therapeutic modality.